Symposia

Saturday, 18 September – 17:35 – 18:35 CET

ISS Janssen Satellite Symposium – Is “Standard of Care” a thing in the past in CLL?

17:35 5 mins Introduction

Chair: John Gribben
17:40 15 mins No, “Standard of Care” is not a thing of the past in CLL Carol Moreno
17:50 15 mins Yes, “Standard of Care” is a thing of the past in CLL Paolo Ghia
18:05 15 mins Novel Agents: No longer novel? Steven Coutre
18:15 15 mins Panel discussion All Faculty
18:30 5 mins Closing Remarks
18:35 Adjourn
Sunday, 19 September – 13:45 – 14:45 CEST

ISS BeiGene Satellite Symposium - Evolving Role of BTK Inhibitors in R/R CLL – A Rational Approach to Improving Patient Outcomes

13:45 4 mins Welcome, introduction and objectives

Chair: Anna Schuh
13:49 10 mins A pharmacologist’s view on the rationale for using different BTK inhibitors for R/R CLL Federico Pea
13:59 10 mins Evolving strategies with next generation BTK inhibitors as treatment for R/R CLL patients Wojciech Jurczak
14:09 12 mins 2 Patient Case Reports in R/R CLL Othman Al-Sawaf
14:21 10 mins Panel discussion All Faculty
14:31 14 mins Audience Q&A All Faculty
14:45 Adjourn
Sunday, 19 September – 17:00 – 18:00 CEST

ISS AbbVie Satellite Symposium CLARIFYING COMPLEXITY IN CLL: Optimal management of patients with challenging molecular subtypes

17:00 5 mins Welcome and introduction

Chair: Barbara Eichhorst
17:05 15 mins Understanding challenging molecular subtypes in CLL Anna Schuh
17:20 15 mins Management of CLL with challenging molecular subtypes Barbara Eichhorst
17:35 15 mins Strategies to address unmet needs in challenging
molecular subtypes
Matthew Davids
17:50 10 mins Audience Q&A / close All speakers
18:00 Adjourn
Monday, 20 September – 15:55 – 16:55 CEST

ISS AstraZeneca Satellite Symposium Targeting BTK in CLL: Expert Guidance on Selecting Single-Agent and Combination Therapy

15:55 5 mins Welcome, Introduction, Polling Questions

Chair: Richard Furman
16:00 10 mins The Current Role of BTK Inhibitors in CLL Richard Furman
16:10 35 mins Case Discussions: Practical Guidance on Selecting BTK inhibitor Therapy in CLL All Faculty
16:45 10 mins Summary, Final Thought, Audience Q&A
16:55 Adjourn